Nucleic acid-based technologies have received significant interest in recent years as novel
theranostic strategies for various diseases. The approval by the United States Food and …

Oligonucleotide therapeutics are emerging as a promising class of therapeutics in various
areas of human health. In the long run, oligonucleotides are likely to become a major class …

The genetic basis for most inherited neurodegenerative diseases has been identified, yet
there are limited disease-modifying therapies for these patients. A new class of drugs …

Antisense nucleic acids are single‐stranded oligonucleotides that have been specially
chemically modified, which can bind to RNA expressed by target genes through base …

Antisense oligonucleotides represent a novel therapeutic platform for the discovery of
medicines that have the potential to treat most neurodegenerative diseases. Antisense …

Molecular genetics insight into the pathogenesis of several neurodegenerative diseases,
such as Alzheimer׳ s disease, Parkinson׳ s disease, Huntington׳ s disease and amyotrophic …

Therapeutics that directly target RNAs are promising for a broad spectrum of disorders,
including the neurodegenerative diseases. This is exemplified by the FDA approval of …

Recently, manipulation of gene expression and switching genes on or off highlight the
potential of nucleic acid-based therapies (NA-BTs). Alzheimer's Disease (AD) is a common …

Alzheimer's disease (AD) represents a particular therapeutic challenge because its
aetiology is very complex, with dynamic progression from preclinical to clinical stages …

Parkinson's disease is the second most common progressive neurodegenerative disease
diagnosed mainly based on clinical symptoms caused by loss of nigrostriatal dopaminergic …